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Introduction
The development of a drug is a process of converting a biologi-
cally active compound into a product that is safe and effective, it 
is a long and expensive process. The performance of a drug, the 
??????????????????????????????????????????????????????????????????-
dent on the drug’s properties. Chemical and physical properties 
of a drug determine the drug’s ability to react with the necessary 
components along the path to achieving the desired effect. One 
of the factors determining a drug’s performance and effectiveness 
is the aqueous solubility of the drug (Gareth, 2007).
Solubility of a Compound
?????? ??????? ??????????? ??? ???? ???????????? ??? ?? ??????????
solution in terms of the amount of solute in proportion to 
solvent (McNaught, Wilkinson, 2006). Solubility is the term 
used to describe a solid, liquid, or a gas’s ability to dissolve in 
a solvent. Aqueous solubility of a molecule changes depending 
on the electrostatic charge of the molecule and the degree of 
ionization. The dipoles in the water molecules are attracted to 
the charged molecules forming a shell around the molecule and 
solvating it (Trevor et.al. 2015).
Solubility of a compound depends also on its structure and 
polarity. Polar groups can hydrogen bond with water molecules 
and be solvated, nonpolar groups are insoluble in aqueous solu-
tion. Therefore, the aqueous solubility of a compound increases 
as the number of polar groups on the compound increases. In 
addition, if the polar groups on a compound have the ability to 
ionize in water, the compound will be further soluble. Lipid sol-
uble compounds are those with more nonpolar groups and they 
may contain functional groups such as benzene rings, ethers and 
esters. Amphipathic compounds with polar and non-polar parts 
are soluble in both aqueous and lipid solvents (Gareth, 2007). 
Drug Solubility
Solubility is a fundamental property that must be considered 
when evaluating a drug. The solubility of a drug can range from 
fully soluble, like ethanol in water, to poorly soluble, often referred 
to as insoluble (Clugston, Fleming, 2000). The Biopharmaceutics 
????????????????????? ??????? ??? ?? ?????? ???????????????????????
Drug Administration and is used to regulate and classify drugs 
based on aqueous solubility and membrane permeability. Class 
I drugs have high aqueous solubility and high membrane perme-
ability, Class II drugs have low aqueous solubility and high mem-
brane permeability, Class III have high aqueous solubility and low 
membrane permeability, and Class IV drugs have low aqueous 
solubility and low membrane permeability. Solubility of a drug is 
determined based on the drug’s solubility over a pH range of 1 to 
7.5 and is considered very soluble if the highest dose strength is 
soluble in <250 ml of water. The membrane permeability of a drug 
is measured by the extent of absorption and a drug is considered 
highly permeable when the absorption in humans is > 90% of an 
administered dose (FDA, BCS, 2016). Since cells typically contain 
65% water, a drug must be water soluble to be effective. A drug 
must be absorbed before entering the bloodstream in order for 
the drug to be transported via the systemic circulation to its site 
of action. The more soluble the drug the greater amount of ab-
sorbed drug in the bloodstream. More drug in the bloodstream 
increases the gradient between the bloodstream and the extra-
???????????????????????????????????????????????????????????????????
??????????????????????????????? ???????????? ???????????? ??????????? ???
addition, the more water soluble the drug the higher the bioavail-
ability (Gareth, 2007). The amount of drug that is absorbed by the 
bloodstream, divided by the amount that was administered, is the 
?????????????????????????????????????????? ????????????????????????
Drug absorbed / drug administered = bioavailability of the drug 
(Trevor et. al. 2015).
Oral drugs are the most common form of drug administration. 
???????????????????????????????????????????????????????????????????-
quirements, they are most cost effective, have a high patient com-
?????????????????????????????????????????????????????????????????????
many pharmaceutical companies prefer to produce bioequivalent 
???????????? ????????????? ??????????????????????????????????????????
aqueous solubility and therefore low bioavailability. Oral drugs 
????? ????? ????????? ??? ???? ???????? ???????? ????? ??? ?????? ??? ???
transported to the site of action. Therefore, solubility of a drug is 
an important factor in determining the concentration of a drug 
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industry is the low aqueous solubility of many useful drugs. A drug with a low aqueous solubility will not readily be absorbed by 
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necessary to avoid the obstacle of drug insolubility and many methods have been developed. This paper focuses on the use of 
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
hydrophobic and hydrophilic character and are capable of encapsulating a hydrophobic drug molecule and forming guest-host 
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? ?????????
??????????????????????????????????????? ??????????????????????????? ?????????????????????????????????? ? ???????????????????????????
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ibuprofen, imatinib, praziquantel and camptothecin. In each case the aqueous solubility of the poorly soluble drug was increased 
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that is required to achieve a desired response. More than 40% of 
pharmaceutical developments are poorly soluble in water. Low 
solubility of a drug slows the absorption rate, decreasing the bio-
availability. Thus, solubility enhancement methods are necessary. 
Increasing a drug’s solubility is a challenge faced by the drug de-
velopment industry, especially the solubility of oral drugs (Savjani 
et. al. 2012). Increasing the solubility of Class II drugs that have 
low solubility and high permeability would be very productive. 
The rate limiting step for Class II drugs, according to the BCS, is 
the insolubility of the drug, therefore increasing the solubility will 
increase the bioavailability of those drugs. 
There are many methods that are currently used to increase 
the solubility of new chemical entities (NCE’s). There are phys-
??????????????????????????????? ??????????????????????????? ???
increase its solubility. Particle size reduction can be employed, as 
well as solid dispersion, nanosuspension, colloidal particles, and 
changes to the crystal form. Additionally, chemical changes to pH 
as well as complexation and salt formation affect the solubility 
(Savjani et. al. 2012). 
Other methods include the use of surfactants, micelles, lipo-
somes and inclusion complexes (Gareth, 2007). These methods 
utilize the hydrophobic effect in increasing the solubility of a mol-
ecule. Cyclodextrins and cyclodextrin derivatives form inclusion 
complexes with insoluble drugs. Inclusion complexes apply guest-
host chemistry in the formation of the complex. This paper will 
focus on cyclodextrins and cyclodextrin derivatives as a method 
to increase the solubility of a poorly soluble drug.
Methods
This study was completed by analyzing various articles collect-
ed from databases including Touro Library and PubMed. The re-
search collected mainly explored cyclodextrins and their ability 
to form guest-host complexes.
Discussion:
Cyclodextrin and Cyclodextrin Derivatives 
Cyclodextrins (CD’s), and their derivatives are amphipathic mol-
ecules capable of forming guest-host complexes with drug mol-
ecules. The complex improves the drug solubility and ultimately 
the bioavailability of insoluble drugs. Cyclodextrins are used as a 
drug delivery system because of their potential to change phys-
ical, chemical and biological properties of a drug by forming a 
guest-host complex (Gareth, 2007). From a microscopial point 
of view, each guest molecule is micro-encapsulated leading to 
changes in the chemical and physical properties of the molecule. 
Cyclodextrins and their derivatives can improve the solubility of 
a molecule, modify a liquid substance to a powder, and mask a bad 
taste, smell or color of a drug (Chaudhary, Patel, 2013).
Cyclodextrin Structure
Cyclodextrins are cylindrical oligosaccharides typically made up 
of six, seven, or eight glucose units. The cyclodextrin ring form is 
composed of ?-D-glucopyranoside units with 1?4 linkage like 
in amylose (Gareth, 2007). When glucose is degraded by the en-
zyme glucosyltransferase, a product of the chain splitting can un-
dergo an intramolecular reaction to form cyclic molecules, cy-
clodextrins. Each glucose molecule in the cyclodextrin contains 
two secondary alcohols and a primary alcohol. Alpha (?), beta 
(?), or gamma (?) cyclodextrins, depending on whether they 
contain six, seven, or eight glycosyl units respectively, are classi-
???????????????????????????????????????????????????????????????
are hydroxypropyl-?-cyclodextrin, randomly methylated-?-cy-
clodextrin, and sulfobutylether-?-cyclodextrin. These deriva-
tives are often preferred due to their enhanced physiochemical 
and biopharmaceutical properties (Gidwani, Vyas, 2015). 
Cyclodextrin Synthesis
B. macerans is the microbe responsible for the formation of 
cyclodextrins. A method to synthesize cyclodextrins is to treat 
starch with amylase from Bacillus macerans. A crude product 
of cyclodextrin is then obtained with about 60% ?CD, 20% 
?CD, and 20% ?CD. The product also contains small amounts 
of other materials including proteins. To purify the different 
????????? ??????????????, ?, ??????????????????????????? ??????????
??????????????????????????????????????????????????????????
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cyclodextrin derivatives, various forms of glucosyltransferases 
are genetically engineered. These glucosyltransferases are active 
???????????????????????????????????????????????????????????? ???
glucosyltransferase enzymes distinguish the six, seven, or eight 
glucopyranose units from the non-reducing end of an amylose 
??????????????????????????????????????????????????????????????-
tive (Brewster, Loftsson, 2007).
Hydropathy of Cyclodextrin
Cyclodextrins are amphipathic molecules. They have hydropho-
bic and hydrophilic character. Cyclodextrins have a hydropho-
bic interior and hydrophilic exterior. The polar exterior of the 
cyclodextrin forms hydrogen bonds with the aqueous solution. 
The hydrophobic effect drives the non-polar portion of the cy-
clodextrin inwards, away from the aqueous solution, forming a 
hydrophobic cavity. This property enables the cyclodextrin to 
form guest-host inclusion complexes with hydrophobic mole-
cules (Chaudhary, Patel, 2013). 
Cyclodextrins can encapsulate many molecules. The nonpo-
lar hydrophobic molecule interacts with the nonpolar groups 
in the interior of the cyclodextrin, while the polar hydroxyl 
groups on the exterior surface of the cyclodextrin are hydro-
philic. Hydrophobic molecules the size of one or two benzene 
????????????? ????? ??????????????????????????????????????????? ???
the complex increase the aqueous solubility of the guest mol-
ecule, often a drug. The interactions between the cyclodextrin 
and the drug form the inclusion complex, the cyclodextrin host 
molecule with the guest drug (Tiwari et. al. 2010).
Cyclodextrin-Drug Complex 
A number of forces are responsible for the complex formation; 
hydrogen bonding, van der Waals interactions, release of con-
formational strain, and exclusion of high energy water bonds 
in the cyclodextrin cavity. Thermodynamic interactions are the 
main drive in the formation of the cyclodextrin-guest complex. 
Thermodynamically, the interaction between the cyclodextrin 
host, the guest molecule, and the solvent, must overall be fa-
vorable in order for the reaction to proceed (Chaudhary, Patel, 
2013). The cyclodextrin complex formation is usually enthalpy 
driven. In an aqueous solution the cyclodextrin cavity contains 
polar water molecules that are readily exchanged for non-po-
lar hydrophobic guest molecules. The water molecules situated 
inside the non-polar environment of the cyclodextrin cavity do 
not have a full complement of hydrogen bonds and are higher 
in energy than the water molecules outside the cyclodextrin. 
Liberating the water molecules that are enthalpy-rich, high in 
energy, is a driving force for the complexation. Sterically, the 
size and certain functional groups of the guest molecule deter-
??????????????????????????????????????????????????????????????????
Additionally, the complex formation is dependent on the chem-
ical properties of the guest molecule (Brewster, Loftsson, 2007).
The formation of the cyclodextrin-drug complex can be 
achieved through several methods. The kneading method is 
a simple and inexpensive method and is therefore the most 
commonly used method for preparing the complex (Savjani et. 
al. 2012). This method converts the cyclodextrin into a paste 
by saturating the cyclodextrin or cyclodextrin derivative with 
water or hydroalcoholic solution. The drug is then added to the 
paste and the mixture is kneaded. The kneading can be done ei-
ther in the laboratory or using machines for large scale achieve-
ment of the complex. An additional method, the lyophilization/
freeze-drying technique, works with a solution of cyclodextrin 
and drug. The solvent in the solution is removed by freezing the 
solution and then drying it by rapidly reducing the pressure, 
generating a powder. The increased surface area of the powder 
enables considerable interactions between the cyclodextrin and 
the drug (Savjani et. al. 2012).
Cyclodextrins can increase the solubility of the guest mol-
ecule in three patterns when graphed with cyclodextrin con-
??????????????????????????????????????????? ??????????? ??????? ??-
crease in drug solubility as the concentration of cyclodextrin 
is increased. AP systems have a curve that deviates in a positive 
direction from the linearity indicating that the cyclodextrin is 
proportionally more effective at higher concentrations. AN 
relationships have a negative deviation from the linearity indi-
cating that at higher concentrations cyclodextrin’s effectiveness 
decreases (Brewster, Loftsson, 2007). 
Complex Dissociation
Once a product of drug-cyclodextrin is obtained, the complex 
must dissociate to release free drug upon reaching the site of 
action. When drug is encapsulated within the cyclodextrin there 
are factors that cause the complex to dissociate and release 
free drug. The drug and cyclodextrin interactions are non-co-
valent interactions that are in dynamic equilibrium, constantly 
associating and dissociating. There are two important factors 
???????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????
lifetime. In a 1:1 complex ratio of drug to cyclodextrin the com-
???????????????????????????????????? ???????????????????????????
K = kf / kt = [DCyD] / [Df] [CyDf] where kf and kt are the 
forward and reverse rate constants, [DCyD] is the complex 
concentration and [Df] and [CyDf] are free drug and free cy-
clodextrin respectively. 
Dilution is a major factor assumed to play a role in the disso-
ciation of the complex. 1000-fold dilution of a drug with a low 
binding constant to cyclodextrin decreased the complexation 
percentage from 98% to 5.7%. The fraction of complexed drug 
decreased from 99.5% to 47.5% in the presence of 1000-fold 
dilution of a drug with a high binding constant to cyclodextrin. 
Therapeutically, the complexed drug is diluted either 
??? ???? ??????? ??? ??? ???? ???????? ?????????????? ???????? ????
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drug-cyclodextrin complex administered via intravenous in-
jection is diluted in the plasma by a factor of 1:3,500, in the 
?????????????????????????????????????????????????????????????????
?????????? ??? ??????? ????????????? ?????? ???????? ???? ????????
resides in the gastrointestinal tract before reaching the site 
of action. 
Drug binding to plasma protein is another factor responsible 
for complex dissociation. If a drug has the ability to bind to 
plasma protein the complex would dissociate further to release 
more free drug according to Le Chatelier’s principle. Drugs with 
a high binding constant to cyclodextrin that have the ability to 
bind moderately to proteins, in 1000-fold dilution, are further 
dissociated and only 31.9% complexed drug remains. If the drug 
binds more tightly to proteins the factor of complexed drug 
decreases to 8.9%. 
Furthermore, if a drug is lipophilic and can be taken up by tissue 
more drug would be released from the complex. The cyclodextrin 
would remain in the aqueous solution and drug would be taken up 
by tissue. This mechanism is especially useful in drug administered 
???????????????????????????????????????????????????????????????
The dissociation process is driven mainly by an increase of 
water molecules in the surrounding environment and happens 
relatively fast. In a dilute environment there is a concentration 
gradient which shifts the equilibrium to the left, dissociating the 
cyclodextrin and the drug, thereby releasing free drug to be 
absorbed. In the body’s dynamic environment, it is not likely 
that the drug will encounter another cyclodextrin with which 
to form a complex and in this way it remains free in the solution 
(Chaudhary, Patel, 2013).
Complexed Drug Pharmacokinetics
The effect of cyclodextrins on the pharmacokinetics of com-
plexed drug must be considered before cyclodextrin complex-
ation can be applied. Kurkov et. al. studied the effect of com-
plexation on the pharmacokinetics of close to 200 drugs. The 
results concluded that the hydroxypropyl-?-cyclodextrin does 
???? ????? ?? ??????????? ??????? ??? ???? ????????????????? ??? ????
drugs. However, although not altered, some drug is lost due to 
the complexation. The hydrophilic cyclodextrins are excreted 
unchanged by the kidneys and any drug still encapsulated is 
excreted too. This is especially true when the drug has a high 
binding constant to cyclodextrin (Kurkov et. al. 2012).
Toxicological Considerations
??????? ????????????? ?????????????? ???? ???? ????????????? ??-
sorbed in their intact form from the gastrointestinal tract. The 
Cyclodextrins range from 1000 Da to over 2000 Da in molecu-
????????????????????????????????????????????????????????????????
donors and acceptors, therefore they cannot be absorbed in 
their original form. Natural ?-cyclodextrin and ?-cyclodex-
trin cannot be hydrolyzed by human salivary and pancreatic 
amylases and in general oral administration is not associated 
????? ??????????? ???????? ???????? ???? ???????? ????????????????? ???
injection ?-cyclodextrin is mainly excreted unchanged in the 
urine. ?-cyclodextrin is nephrotoxic when administered paren-
terally but non-toxic in the topical, buccal, rectal or oral form 
and can be found in numerous marketed drugs. The metabolism 
of ?-cyclodextrin is similar to that of starch and linear dextrins 
and only small amounts are absorbed intact. After iv injection 
the ?-cyclodextrin is mainly excreted unchanged in the urine 
(Brewster, Loftsson, 2007).
Ibuprofen-Cyclodextrin
?????????? ??? ?? ????????????? ????????????????? ????? ????? ??
used to treat mild to moderate pain and fever. Ibuprofen works 
by inhibiting cyclooxygenase, an enzyme that converts arachi-
donic acid to cyclic endoperoxides. Cyclic endoperoxides are 
??????????? ??? ??????????????? ???????????? ???? ????????????
(PubChem, 2004). 
Ibuprofen is a poorly water soluble drug. Although it contains 
a carboxylic acid functional group which can hydrogen bond 
with water and be solvated, the alkyl groups and the benzene 
ring are non-polar and make the drug poorly soluble. Ibuprofen 
is complexed with cyclodextrin derivatives to increase its solu-
bility (Hussein et. al. 2007). 
Khaled Hussein, et al. conducted a study on the ibupro-
fen-?-cyclodextrin complex (Hussein et. al. 2007). A solid 
complex of ibuprofen, MW 206.3 g/mol, and ?-cyclodextrin, 
MW 1,135.0 g/mol, was prepared. Using controlled Particle 
Deposition (CPD) with supercritical carbon dioxide the ibu-
profen-?-cyclodextrin complex was formed. The CPD method 
dissolves the desired solution in supercritical carbon dioxide 
which then enters the pores of the carrier at extremely high 
pressure and precipitates following a rapid pressure drop. 
The “n-hexane wash” method determined whether the com-
plex was formed. ?-cyclodextrin and its complexes are insol-
uble in n-hexane but the free drug is soluble. The supernatant 
liquid that was insoluble was separated, dried and then analyzed 
by high-performance liquid chromatography (HPLC). HPLC de-
termined the product yield as well as the content of ibuprofen 
in the complex. The inclusion yield of the complex was deter-
mined using the following equation:
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Percent of included ibuprofen= [complexed amount 
of ibuprofen/free amount + complexed amount] x 100 
49.83±3.65 inclusion yield % was calculated. 
Infrared spectroscopy of pure ibuprofen showed all the 
characteristic peaks including the carbonyl peak at 1,706 cm-1. 
The complexed drug’s infrared spectroscopy had a very week 
carbonyl peak indicating that the drug molecule was encapsu-
lated inside the ?-cyclodextrin. Morphological changes were 
also observed. Pure ibuprofen is rough needle-shaped crystals 
and ?-cyclodextrin is parallelogram shaped. The shape of the 
complexed particles appeared smaller in size and different than 
pure drug or pure ?-cyclodextrin. This observation adds to the 
evidence of the ibuprofen-?-cyclodextrin complex formation. 
???????????????? ??????? ????????? ?????????????? ?????????-
tem with a dissolution vessel at pH 5 and 37°C. A sample of 
pure ibuprofen and a sample of complexed ibuprofen, each 
containing 3mg ibuprofen, were added to the vessel. Samples 
???????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
was calculated. Kw corresponds to the time when 63.2% of the 
drug is dissolved. 
The dissolution of pure ibuprofen in vitro at pH 5 showed 
poor dissolution after 15 minutes and after 75 minutes. The 
??????????????????????????????????????????????????????????????
amount, due to the presence of the ?-cyclodextrin. The disso-
lution rate of the complexed product was 0.086±0.002 min-¹, 
the rate of pure ibuprofen was excluded from analysis since it 
did not reach 63.2% within 72 minutes. The dissolved amount of 
drug after 15 minutes was determined to be 71.9±3.62% for the 
complexed prepared using the CPD method, and 22.0±3.56% 
for pure drug. After 72 minutes, 93.5±2.89% of drug dissolved 
from the ibuprofen-?-cyclodextrin complex and from pure 
ibuprofen sample only 59.5±4.86% of drug dissolved. The com-
????????????????????????????????????????????????????????????
Imatinib-Cyclodextrin
Imatinib, known as Gleevec, is an oral tablet or a capsule used 
for the treatment of Philadelphia chromosome positive chronic 
myeloid leukemia (CML) or gastrointestinal stromal tumors. 
Imatinib works by inhibiting protein tyrosine kinase, the growth 
factor receptor that causes unregulated cell growth of cancer 
cells (PubChem, 2005).
Aqueous solubility of imatinib is charge dependent and varies 
depending on the pH. The active compound, imatinib, can be 
mono, di, tri and tetra protonated. The more protonated the 
compound the greater the overall charge of the compound. 
Increased charge increases the aqueous solubility. At a pH below 
5.5 the formation of different protonated species of imatinib 
results in a charged drug that is water soluble. However, the free 
base form of imatinib is neutral, uncharged, and therefore poorly 
soluble. To increase the aqueous solubility of the free base form 
of imatinib, the drug was complexed with ?-cyclodextrin and 
with randomly methylated ?-cyclodextrin (RAMEB). Szabolcs 
Beni, et al. performed a study determining the effectiveness of 
cyclodextrin and cyclodextrin derivatives in increasing the solu-
bility of the neutral drug form (Beni et. al. 2007).
In a solution of Na2CO3 at a pH of 10.5, 2 mg of imatinib 
was added to a 1 ml solution of varying concentrations of ?-cy-
clodextrin, 0-13 mM. The mixture was shaken for two days at 
25.0 ± 0.5°C and a complexed product of 1:1 stoichiometry 
was formed.
The aqueous solubility of the free base form of imatinib was 
enhanced by complexing it with ?-cyclodextrin. At a pH of 10 
the linear AL phase solubility diagram indicated the improve-
ment in the solubility of the drug. With increased cyclodextrin 
concentration, the solubility of the drug increased linearly, com-
plexation increased the drug solubility tenfold.
Titration of pure imatinib with KOH precipitated above a 
pH of 6.5. Titration of 1mM imatinib in the presence of four-
fold ?-cyclodextrin or randomly methylated ?-cyclodextrin 
(RAMEB) did not precipitate due to the complex’s effect on 
the solubility. The most stable form of the imatinib-cyclodex-
trin complex formed with the neutral form of imatinib. This is 
because the neutral imatinib is most hydrophobic and interacts 
most with the hydrophobic interior of the cyclodextrin. The af-
?????????? ????????????????????????????????????????????????????
on the drug increased.
??? ???? ????????? ?????? ?????????? ??????? ?????????? ????
non-covalent molecular interactions. At a titration of pH 3.5 the 
predominant imatinib species was the deprotonated form. The 
mono and tri protonated forms were present in smaller quan-
tities. Interactions between the imatinib forms and the ?-cyclo-
dextrin was evident. The data collected suggests that the ben-
zamide fragment of imatinib is involved in the inclusion complex. 
2D ROESY NMR spectra was recorded at the same pH to 
verify the data. The evidence suggested that the imatinib inclu-
sion proceeds through the narrower part of the cyclodextrin 
host. For steric reasons the inclusion proceeds in an unusual 
way, through the narrower part of the cyclodextrin. The result 
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of the study concluded that a tenfold increase in the imatinib 
solubility was achieved with 12mM ?-cyclodextrin complex-
ation. The increased aqueous solubility of imatinib greatly in-
creases the effectiveness of the anti-cancer drug.
Praziquantel-Cyclodextrin
Praziquantel (PZQ) is a Class II drug, according to the BCS, 
used for the treatment of schistosomiasis. The drug works by 
causing severe spasm and paralysis to the worms’ muscles and 
the worms are then destroyed in the intestines or passed in the 
???????????????????????????????????????????????????????????????????
permeability but low aqueous solubility. The low aqueous solu-
bility is due to its lipophilic character (PubChem, 2005).
As a Class II drug, a high dose of praziquantel is necessary in 
order for it to be effective. Improving the aqueous solubility of 
?????????????????????????????????????????????????????????????????????
as a BCS-Class I compound. To increase the aqueous solubility 
of praziquantel the drug was complexed with ?-cyclodextrin 
and hydroxypropyl-?-cyclodextrin. A study was conducted to 
determine whether this Class II drug can be complexed with cy-
clodextrin and behave like a Class I drug (Maragos et. al. 2009).
The praziquantel-cyclodextrin complexes were formed via 
the kneading method. 0.080 grams of praziquantel was mixed 
with cyclodextrin in varying ratios; 1:1, 1:2, and 1:4 molar ratios. 
The complexed praziquantel-?-cyclodextrin reached equilibra-
tion within 12 hours and the praziquantel-hydroxypropyl-?-cy-
clodextrin complex reached equilibration after a 24 hour 
period. Heating the samples at 70°C for an hour prior to the 
experiment accelerated the reaction and also increased the for-
mation of the praziquantel-cyclodextrin complex. The concen-
tration of praziquantel in the binary system remained constant 
while it was in a shaking bath at 25°C for 72 hours. 
The aqueous solubility of the lipophilic drug had a 4-5-fold 
increase upon complexation with cyclodextrin. Calculations 
of the praziquantel solubility in 0.01 M cyclodextrin versus 
the solubility of praziquantel without cyclodextrin calculated 
a solubility enhancement factor of 4.5. Preheating the samples 
at 70°C for one hour prior to the experiment increased the 
solubility enhancement factor; a factor of 5.5 was calculated for 
the praziquantel-?-cyclodextrin complex and 6.0 for the prazi-
quantel-hydroxypropyl-?-cyclodextrin complex. Preheating the 
sample before complexation enhanced the drug complexation 
by increasing the dissolved amount of praziquantel that inter-
acted with the cyclodextrin to form inclusion complexes.
The content of praziquantel in the product was determined 
spectrometrically. The isoquinoline ring of the praziquantel in-
serted in the cyclodextrin cavity. The phase solubility diagrams 
were linear. The praziquantel complexation was stronger with 
?-cyclodextrin than with the hydroxypropyl-?-cyclodextrin 
derivative as revealed by the complexation constants, K values, 
????????????????????????????????????????????????????????
??????????????????? ?????????????????????????????????????
???????????????????????????????????????????????????
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obtained from the diagram. Furthermore, the complexation en-
hancement as a result of preheating the sample was more signif-
icant in the hydroxypropyl-???????????????????????????????????
in the K values. 
Praziquantel complexation with different molar ratios of 
cyclodextrin was studied. The praziquantel complex with 
?-cyclodextrin had the highest drug concentration in a 1:2 
praziquantel-cyclodextrin ratio. The optimum praziquantel-hy-
droxypropyl-?-cyclodextrin complex molar ratio was 1:4. The 
different behaviors of the cyclodextrin derivatives are a result of 
hydrogen bond formation between the drug and cyclodextrin. 
After complexation with ?-cyclodextrin and hydroxypro-
pyl-?-cyclodextrin the drug was reevaluated in terms of the 
BCS. The solubility/dose ratio, in relation to the dose and in-
testinal content, was calculated using solubility values of prazi-
quantel in the presence and absence of ?-cyclodextrin and 
hydroxypropyl-?-cyclodextrin. At a low dose of 150 mg the 
praziquantel complexed with ?-cyclodextrin or hydroxypro-
pyl-?-cyclodextrin had a higher solubility/dose ratio than pure 
drug. The solubility was increased while the dose decreased. The 
???????????????????????????????????????????????????????????????
Class I drug. 
Camptothecin-Cyclodextrin
Camptothecin is an antineoplastic agent that displays broad spec-
trum activity in the treatment of various cancers. Camptothecin 
is used against human lung cancer, prostate, breast, colon, stom-
ach, and ovarian carcinomas and in the treatment of melanoma, 
lymphomas, and sarcomas. An alkaloid isolated from the bark 
of the Chinese tree Camptotheca acuminata, camptothecin 
works by inhibiting the enzyme topoisomerase I. Inhibition of 
topoisomerase I prevents DNA relegation leading to DNA 
damage and apoptosis (PubChem, 2005). Camptothecin is prac-
tically insoluble in aqueous solution at a pH above 7 the drug is 
converted to a water soluble but less active carboxylate form. 
Jichao Kang, et al. performed a study complexing camptothecin 
with cyclodextrin in attempt to increase the solubility of the 
pharmaceutically important drug (Kang et. al. 2002).
The solubility of the drug complexed with cyclodextrin was 
determined by placing 5 mg of camptothecin in 1.0 ml of a 0.02 
M HCl solution containing different amounts of cyclodextrin. 
Analysis of the results gave a linear graph, the solubility of 
camptothecin increased linearly with the increasing concentra-
tions of various cyclodextrins. Camptothecin in the ?-cyclodex-
trin complex had the highest increase in solubility, increasing 
by about six-fold. ?-cyclodextrin increased the camptothecin 
solubility three-fold and ?-cyclodextrin increased the drug’s sol-
????????????????????????????????????????????????????-CD ex-
hibited the greatest increase in camptothecin’s solubility. At 25% 
weight / volume concentration of RDM-?-CD, the solubility of 
camptothecin increased by a factor of 170. The methyl groups 
???????????????????????????????????????????????????????????????????
derivative by disrupting the intramolecular hydrogen bonding 
and enlarging the cyclodextrin cavity.
Conclusion
??????????????????????? ??????????????????????????????????????????
of a drug. The low aqueous solubility of many pharmaceutical 
developments is an area of constant research. This paper stud-
ied the effect of cyclodextrins on the solubility of poorly soluble 
drugs. Cyclodextrins and their derivatives, by forming guest-
host complexes, encapsulate an insoluble drug and increase its 
aqueous solubility. The cyclodextrin carries the drug through 
the aqueous solution and the complex dissociates upon reach-
ing the site of action. The cyclodextrin drug carrier transports 
???????????????????????????????????????????????????????????????-
cant harm to the patient.
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